FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020809327> ?p ?o ?g. }

• W2020809327 endingPage "e23" @default.
• W2020809327 startingPage "e22" @default.
• W2020809327 abstract "To the Editor: A 2-day-old black female newborn, born via cesarean section after premature rupture of membranes (34 weeks' gestation), had a collodion membrane. Stellate cracking was present over the entire cutaneous surface (Fig 1). There were no nail abnormalities, bullae, ectropion, or eclabium. The mother was treated for severe psoriasis and psoriatic arthritis with a 7.5-mg/kg infusion of infliximab every 6 weeks throughout pregnancy, and for 6 months before conception. She took no other medications during her pregnancy. Newborn genetic screening, complete blood cell count, and comprehensive metabolic panel test results were within normal limits, and there was no history of consanguinity. There was no family history of bullous congenital ichthyosiform erythroderma or lamellar ichthyosis. Treatment was initiated with a petrolatum-based ointment (Aquaphor, Beiersdorf Inc, Wilton, CT). The collodion membrane shed completely and the skin normalized over 2 months. The skin was normal-appearing at age 1 year. The mean age of onset of psoriasis is during the 20s and 30s, the peak childbearing years. Although the hormonal changes of pregnancy can improve psoriasis, approximately 20% worsen.1Murase J.E. Chan K.K. Garite T.J. Cooper D.M. Weinstein G.D. Hormonal effect on psoriasis in pregnancy and postpartum.Arch Dermatol. 2005; 141: 601-606Crossref PubMed Scopus (135) Google Scholar Psoriatic arthritis, severe in 5% of patients, can be quite destructive. Inflammatory cytokines such as interleukin 17 and tumor necrosis factor (TNF)-alfa inhibit the T-helper cell type 17 axis inducing inflammation and defects in keratinocyte differentiation producing psoriatic plaques.2Wang C.Q.F. Akalu Y.T. Suarez-Farinas M. Gonzalez J. Mitsui H. Lowes M.A. et al.IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis.J Invest Dermatol. 2013; 133: 2741-2752Crossref PubMed Scopus (131) Google Scholar TNF-alfa inhibitors, such as infliximab, are remarkably effective in controlling both psoriasis and psoriatic arthritis.2Wang C.Q.F. Akalu Y.T. Suarez-Farinas M. Gonzalez J. Mitsui H. Lowes M.A. et al.IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis.J Invest Dermatol. 2013; 133: 2741-2752Crossref PubMed Scopus (131) Google Scholar Infliximab, a complete chimeric monoclonal IgG1 antibody, is a potent anti–TNF-alfa biologic agent delivered by infusion. It is designated Food and Drugs Administration (FDA) category B because animal reproduction studies did not demonstrate a risk but well-controlled studies in human pregnancy have not been done.3Carter J.D. Ladhani A. Ricca L.R. Valeriano J. Vasey F.B. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drugs Administration database.J Rheumatol. 2009; 36: 635-641Crossref PubMed Scopus (229) Google Scholar The Fc receptors on trophoblasts help to actively transport all biological agents with an IgG Fc region. Therefore, the transplacental passage of monoclonal antibodies such as infliximab and adalimumab is greater than in etanercept. An FDA database review of 41 children born to mothers taking a TNF antagonist demonstrated congenital anomalies in 24 children (59%).3Carter J.D. Ladhani A. Ricca L.R. Valeriano J. Vasey F.B. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drugs Administration database.J Rheumatol. 2009; 36: 635-641Crossref PubMed Scopus (229) Google Scholar Of the anomalies reported, 56% were part of the vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies, and limb abnormalities (VACTERL) spectrum, but only 1 child was diagnosed with VACTERL. A retrospective analysis of pregnancy outcomes of 32 women exposed to anti–TNF-alfa inhibitors demonstrated no increased risk to the patients and fetuses, although the paucity of data precluded a recommendation for regular use in pregnancy.4Hyrich K.L. Symmons D.P.M. Watson K.D. Silman A.J. Pregnancy outcome in women who were exposed to anti–tumor necrosis factor agents: results from a national population register.Arthritis Rheum. 2006; 54: 2701-2702Crossref PubMed Scopus (90) Google Scholar Although collodion membrane associated with anti–TNF biologic agents has not been reported to our knowledge, there are several examples of paradoxical inducement of keratinization abnormalities. New-onset psoriasis has occurred in a series of patients with rheumatologic conditions treated with TNF-alfa inhibitors.5Sfikakis P.P. Iliopoulos A. Elezoglou A. Kittas C. Stratigos A. Psoriasis induced by anti–tumor necrosis factor therapy: a paradoxical adverse reaction.Arthritis Rheum. 2005; 52: 2513-2518Crossref PubMed Scopus (276) Google Scholar, 6De Gannes G.C. Ghoreishi M. Pope J. Russell A. Bell D. Adams S. et al.Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions.Arch Dermatol. 2007; 143: 223-231Crossref PubMed Scopus (299) Google Scholar The pathogenesis of these paradoxical reactions may be the result of overexpression of interferon because of the cross-regulation between TNF-alfa and interferon. Perhaps a similar mechanism may explain the translucent, tight, and parchment paper–like “collodion membrane” in our patient after prenatal exposure to infliximab. Collodion membrane secondary to ichthyoses can be excluded because this child's condition was self-limited. Considering potential side effects of alternative systemic agents, TNF-alfa inhibitors should remain in the armamentarium for pregnant psoriatic patients. Etanercept may be the safest of this class because of its lower level transplacental passage." @default.
• W2020809327 created "2016-06-24" @default.
• W2020809327 creator A5026831242 @default.
• W2020809327 creator A5035276255 @default.
• W2020809327 creator A5070668833 @default.
• W2020809327 creator A5074304536 @default.
• W2020809327 date "2014-07-01" @default.
• W2020809327 modified "2023-10-11" @default.
• W2020809327 title "Collodion-like membrane in a newborn exposed to infliximab" @default.
• W2020809327 cites W2038763425 @default.
• W2020809327 cites W2047295530 @default.
• W2020809327 cites W2078429934 @default.
• W2020809327 cites W2111411787 @default.
• W2020809327 cites W2149827116 @default.
• W2020809327 cites W2152559121 @default.
• W2020809327 doi "https://doi.org/10.1016/j.jaad.2014.01.856" @default.
• W2020809327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24947707" @default.
• W2020809327 hasPublicationYear "2014" @default.
• W2020809327 type Work @default.
• W2020809327 sameAs 2020809327 @default.
• W2020809327 citedByCount "14" @default.
• W2020809327 countsByYear W20208093272014 @default.
• W2020809327 countsByYear W20208093272015 @default.
• W2020809327 countsByYear W20208093272016 @default.
• W2020809327 countsByYear W20208093272017 @default.
• W2020809327 countsByYear W20208093272022 @default.
• W2020809327 countsByYear W20208093272023 @default.
• W2020809327 crossrefType "journal-article" @default.
• W2020809327 hasAuthorship W2020809327A5026831242 @default.
• W2020809327 hasAuthorship W2020809327A5035276255 @default.
• W2020809327 hasAuthorship W2020809327A5070668833 @default.
• W2020809327 hasAuthorship W2020809327A5074304536 @default.
• W2020809327 hasBestOaLocation W20208093271 @default.
• W2020809327 hasConcept C126322002 @default.
• W2020809327 hasConcept C16005928 @default.
• W2020809327 hasConcept C17991360 @default.
• W2020809327 hasConcept C2776260265 @default.
• W2020809327 hasConcept C2776292323 @default.
• W2020809327 hasConcept C2777138892 @default.
• W2020809327 hasConcept C2779234561 @default.
• W2020809327 hasConcept C2779483664 @default.
• W2020809327 hasConcept C2780564577 @default.
• W2020809327 hasConcept C54355233 @default.
• W2020809327 hasConcept C71924100 @default.
• W2020809327 hasConcept C86803240 @default.
• W2020809327 hasConceptScore W2020809327C126322002 @default.
• W2020809327 hasConceptScore W2020809327C16005928 @default.
• W2020809327 hasConceptScore W2020809327C17991360 @default.
• W2020809327 hasConceptScore W2020809327C2776260265 @default.
• W2020809327 hasConceptScore W2020809327C2776292323 @default.
• W2020809327 hasConceptScore W2020809327C2777138892 @default.
• W2020809327 hasConceptScore W2020809327C2779234561 @default.
• W2020809327 hasConceptScore W2020809327C2779483664 @default.
• W2020809327 hasConceptScore W2020809327C2780564577 @default.
• W2020809327 hasConceptScore W2020809327C54355233 @default.
• W2020809327 hasConceptScore W2020809327C71924100 @default.
• W2020809327 hasConceptScore W2020809327C86803240 @default.
• W2020809327 hasIssue "1" @default.
• W2020809327 hasLocation W20208093271 @default.
• W2020809327 hasLocation W20208093272 @default.
• W2020809327 hasOpenAccess W2020809327 @default.
• W2020809327 hasPrimaryLocation W20208093271 @default.
• W2020809327 hasRelatedWork W1964002779 @default.
• W2020809327 hasRelatedWork W1990764331 @default.
• W2020809327 hasRelatedWork W2026533139 @default.
• W2020809327 hasRelatedWork W2048011213 @default.
• W2020809327 hasRelatedWork W2107724362 @default.
• W2020809327 hasRelatedWork W2124642801 @default.
• W2020809327 hasRelatedWork W2360064292 @default.
• W2020809327 hasRelatedWork W2560958410 @default.
• W2020809327 hasRelatedWork W3143241563 @default.
• W2020809327 hasRelatedWork W4317932061 @default.
• W2020809327 hasVolume "71" @default.
• W2020809327 isParatext "false" @default.
• W2020809327 isRetracted "false" @default.
• W2020809327 magId "2020809327" @default.
• W2020809327 workType "article" @default.